Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine.

Folegatti PM, Bellamy D, Roberts R, Powlson J, Edwards NJ, Mair CF, Bowyer G, Poulton I, Mitton CH, Green N, Berrie E, Lawrie AM, Hill AVS, Ewer KJ, Hermon-Taylor J, Gilbert SC.

Vaccines (Basel). 2019 May 15;7(2). pii: E40. doi: 10.3390/vaccines7020040.

2.

Prime and target immunization protects against liver-stage malaria in mice.

Gola A, Silman D, Walters AA, Sridhar S, Uderhardt S, Salman AM, Halbroth BR, Bellamy D, Bowyer G, Powlson J, Baker M, Venkatraman N, Poulton I, Berrie E, Roberts R, Lawrie AM, Angus B, Khan SM, Janse CJ, Ewer KJ, Germain RN, Spencer AJ, Hill AVS.

Sci Transl Med. 2018 Sep 26;10(460). pii: eaap9128. doi: 10.1126/scitranslmed.aap9128.

PMID:
30257955
3.

Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells.

Jin J, Tarrant RD, Bolam EJ, Angell-Manning P, Soegaard M, Pattinson DJ, Dulal P, Silk SE, Marshall JM, Dabbs RA, Nugent FL, Barrett JR, Hjerrild KA, Poulsen L, Jørgensen T, Brenner T, Baleanu IN, Parracho HM, Tahiri-Alaoui A, Whale G, Moyle S, Payne RO, Minassian AM, Higgins MK, Detmers FJ, Lawrie AM, Douglas AD, Smith R, de Jongh WA, Berrie E, Ashfield R, Draper SJ.

NPJ Vaccines. 2018 Aug 17;3:32. doi: 10.1038/s41541-018-0071-7. eCollection 2018.

4.

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions.

Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F, de Graaf H, Brendish NJ, Poulton ID, Griffiths OJ, Edwards NJ, Jin J, Labbé GM, Alanine DG, Siani L, Di Marco S, Roberts R, Green N, Berrie E, Ishizuka AS, Nielsen CM, Bardelli M, Partey FD, Ofori MF, Barfod L, Wambua J, Murungi LM, Osier FH, Biswas S, McCarthy JS, Minassian AM, Ashfield R, Viebig NK, Nugent FL, Douglas AD, Vekemans J, Wright GJ, Faust SN, Hill AV, Long CA, Lawrie AM, Draper SJ.

JCI Insight. 2017 Nov 2;2(21). pii: 96381. doi: 10.1172/jci.insight.96381.

5.

Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.

Payne RO, Silk SE, Elias SC, Milne KH, Rawlinson TA, Llewellyn D, Shakri AR, Jin J, Labbé GM, Edwards NJ, Poulton ID, Roberts R, Farid R, Jørgensen T, Alanine DG, de Cassan SC, Higgins MK, Otto TD, McCarthy JS, de Jongh WA, Nicosia A, Moyle S, Hill AV, Berrie E, Chitnis CE, Lawrie AM, Draper SJ.

JCI Insight. 2017 Jun 15;2(12). pii: 93683. doi: 10.1172/jci.insight.93683. eCollection 2017 Jun 15.

6.

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.

Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, Biedenkopf N, Krähling V, Tully CM, Edwards NJ, Bentley EM, Samuel D, Labbé G, Jin J, Gibani M, Minhinnick A, Wilkie M, Poulton I, Lella N, Roberts R, Hartnell F, Bliss C, Sierra-Davidson K, Powlson J, Berrie E, Tedder R, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Mbaya OT, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Wright E, Becker S, Graham BS, Koup RA, Levine MM, Volkmann A, Chaplin P, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV.

N Engl J Med. 2016 Apr 28;374(17):1635-46. doi: 10.1056/NEJMoa1411627. Epub 2015 Jan 28.

7.

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.

de Barra E, Hodgson SH, Ewer KJ, Bliss CM, Hennigan K, Collins A, Berrie E, Lawrie AM, Gilbert SC, Nicosia A, McConkey SJ, Hill AV.

PLoS One. 2014 Dec 18;9(12):e115161. doi: 10.1371/journal.pone.0115161. eCollection 2014.

8.

Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.

Hodgson SH, Ewer KJ, Bliss CM, Edwards NJ, Rampling T, Anagnostou NA, de Barra E, Havelock T, Bowyer G, Poulton ID, de Cassan S, Longley R, Illingworth JJ, Douglas AD, Mange PB, Collins KA, Roberts R, Gerry S, Berrie E, Moyle S, Colloca S, Cortese R, Sinden RE, Gilbert SC, Bejon P, Lawrie AM, Nicosia A, Faust SN, Hill AV.

J Infect Dis. 2015 Apr 1;211(7):1076-86. doi: 10.1093/infdis/jiu579. Epub 2014 Oct 21.

9.

Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.

Hodgson SH, Choudhary P, Elias SC, Milne KH, Rampling TW, Biswas S, Poulton ID, Miura K, Douglas AD, Alanine DG, Illingworth JJ, de Cassan SC, Zhu D, Nicosia A, Long CA, Moyle S, Berrie E, Lawrie AM, Wu Y, Ellis RD, Hill AV, Draper SJ.

Mol Ther. 2014 Dec;22(12):2142-54. doi: 10.1038/mt.2014.157. Epub 2014 Aug 26.

10.

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.

Kimani D, Jagne YJ, Cox M, Kimani E, Bliss CM, Gitau E, Ogwang C, Afolabi MO, Bowyer G, Collins KA, Edwards N, Hodgson SH, Duncan CJ, Spencer AJ, Knight MG, Drammeh A, Anagnostou NA, Berrie E, Moyle S, Gilbert SC, Soipei P, Okebe J, Colloca S, Cortese R, Viebig NK, Roberts R, Lawrie AM, Nicosia A, Imoukhuede EB, Bejon P, Chilengi R, Bojang K, Flanagan KL, Hill AV, Urban BC, Ewer KJ.

Mol Ther. 2014 Nov;22(11):1992-2003. doi: 10.1038/mt.2014.109. Epub 2014 Jun 16.

11.

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.

Ewer KJ, O'Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, Goodman AL, Edwards NJ, Elias SC, Halstead FD, Longley RJ, Rowland R, Poulton ID, Draper SJ, Blagborough AM, Berrie E, Moyle S, Williams N, Siani L, Folgori A, Colloca S, Sinden RE, Lawrie AM, Cortese R, Gilbert SC, Nicosia A, Hill AV.

Nat Commun. 2013;4:2836. doi: 10.1038/ncomms3836.

12.

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.

Borthwick N, Ahmed T, Ondondo B, Hayes P, Rose A, Ebrahimsa U, Hayton EJ, Black A, Bridgeman A, Rosario M, Hill AV, Berrie E, Moyle S, Frahm N, Cox J, Colloca S, Nicosia A, Gilmour J, McMichael AJ, Dorrell L, Hanke T.

Mol Ther. 2014 Feb;22(2):464-475. doi: 10.1038/mt.2013.248. Epub 2013 Oct 31.

13.

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.

Ogwang C, Afolabi M, Kimani D, Jagne YJ, Sheehy SH, Bliss CM, Duncan CJ, Collins KA, Garcia Knight MA, Kimani E, Anagnostou NA, Berrie E, Moyle S, Gilbert SC, Spencer AJ, Soipei P, Mueller J, Okebe J, Colloca S, Cortese R, Viebig NK, Roberts R, Gantlett K, Lawrie AM, Nicosia A, Imoukhuede EB, Bejon P, Urban BC, Flanagan KL, Ewer KJ, Chilengi R, Hill AV, Bojang K.

PLoS One. 2013;8(3):e57726. doi: 10.1371/journal.pone.0057726. Epub 2013 Mar 19.

14.

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.

Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, Collins KA, Edwards NJ, Douglas AD, Anagnostou NA, Ewer KJ, Havelock T, Mahungu T, Bliss CM, Miura K, Poulton ID, Lillie PJ, Antrobus RD, Berrie E, Moyle S, Gantlett K, Colloca S, Cortese R, Long CA, Sinden RE, Gilbert SC, Lawrie AM, Doherty T, Faust SN, Nicosia A, Hill AV, Draper SJ.

Mol Ther. 2012 Dec;20(12):2355-68. doi: 10.1038/mt.2012.223. Epub 2012 Oct 23.

15.

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.

Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O'Hara GA, Halstead FD, Ewer KJ, Mahungu T, Spencer AJ, Miura K, Poulton ID, Dicks MD, Edwards NJ, Berrie E, Moyle S, Colloca S, Cortese R, Gantlett K, Long CA, Lawrie AM, Gilbert SC, Doherty T, Nicosia A, Hill AV, Draper SJ.

PLoS One. 2012;7(2):e31208. doi: 10.1371/journal.pone.0031208. Epub 2012 Feb 21.

16.

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.

O'Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD, Goodman AL, Edwards NJ, Reyes-Sandoval A, Bird P, Rowland R, Sheehy SH, Poulton ID, Hutchings C, Todryk S, Andrews L, Folgori A, Berrie E, Moyle S, Nicosia A, Colloca S, Cortese R, Siani L, Lawrie AM, Gilbert SC, Hill AV.

J Infect Dis. 2012 Mar 1;205(5):772-81. doi: 10.1093/infdis/jir850. Epub 2012 Jan 24.

17.

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.

Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, Williams AR, Halstead FD, Moretz SE, Miura K, Epp C, Dicks MD, Poulton ID, Lawrie AM, Berrie E, Moyle S, Long CA, Colloca S, Cortese R, Gilbert SC, Nicosia A, Hill AV, Draper SJ.

Mol Ther. 2011 Dec;19(12):2269-76. doi: 10.1038/mt.2011.176. Epub 2011 Aug 23.

18.

Hydrogen peroxide vapour (HPV) inactivation of adenovirus.

Berrie E, Andrews L, Yezli S, Otter JA.

Lett Appl Microbiol. 2011 May;52(5):555-8. doi: 10.1111/j.1472-765X.2011.03033.x. Epub 2011 Mar 21.

19.

Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.

Straathof KC, Rao K, Eyrich M, Hale G, Bird P, Berrie E, Brown L, Adams S, Schlegel PG, Goulden N, Gaspar HB, Gennery AR, Landais P, Davies EG, Brenner MK, Veys PA, Amrolia PJ.

Lancet. 2009 Sep 12;374(9693):912-20. doi: 10.1016/S0140-6736(09)60945-4. Epub 2009 Sep 2.

PMID:
19729196
20.

Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia.

Glatting G, Müller M, Koop B, Hohl K, Friesen C, Neumaier B, Berrie E, Bird P, Hale G, Blumstein NM, Waldmann H, Bunjes D, Reske SN.

J Nucl Med. 2006 Aug;47(8):1335-41.

21.

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L.

N Engl J Med. 2005 Jun 23;352(25):2598-608.

22.

Design and manufacture of monoclonal antibodies for radioimmunotherapy.

Hale G, Berrie E, Bird P.

Q J Nucl Med Mol Imaging. 2004 Dec;48(4):258-66. Review.

23.

Manufacture and quality control of CAMPATH-1 antibodies for clinical trials.

Phillips J, Drumm A, Harrison P, Bird P, Bhamra K, Berrie E, Hale G.

Cytotherapy. 2001;3(3):233-42.

PMID:
12171730
24.

Sequence variation in the early genes E1E4, E6 and E7 of human papilloma virus type 6.

Krige D, Mills HR, Berrie EL, Doherty NC, Jones DK, Ryan CA, Davies H, Myint S, McCance DJ, Layton GT, French TJ.

Virus Res. 1997 Jun;49(2):187-91.

PMID:
9213393
25.

Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion.

Griffiths JC, Harris SJ, Layton GT, Berrie EL, French TJ, Burns NR, Adams SE, Kingsman AJ.

J Virol. 1993 Jun;67(6):3191-8.

26.

Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant.

Griffiths JC, Berrie EL, Holdsworth LN, Moore JP, Harris SJ, Senior JM, Kingsman SM, Kingsman AJ, Adams SE.

J Virol. 1991 Jan;65(1):450-6.

27.

Separation and maintenance of primary T and B lymphocytes.

Kinchington D, Berrie E.

Methods Mol Biol. 1990;5:33-41. doi: 10.1385/0-89603-150-0:33.

PMID:
21374113
28.

Castanospermine and other plant alkaloid inhibitors of glucosidase activity block the growth of HIV.

Tyms AS, Berrie EM, Ryder TA, Nash RJ, Hegarty MP, Taylor DL, Mobberley MA, Davis JM, Bell EA, Jeffries DJ, et al.

Lancet. 1987 Oct 31;2(8566):1025-6. No abstract available.

PMID:
2889932
29.

Isolation of human immunodeficiency virus from synovial fluid of a patient with reactive arthritis.

Withrington RH, Cornes P, Harris JR, Seifert MH, Berrie E, Taylor-Robinson D, Jeffries DJ.

Br Med J (Clin Res Ed). 1987 Feb 21;294(6570):484. No abstract available.

30.
31.

Three-year prospective study of HTLV-III/LAV infection in homosexual men.

Weber JN, Wadsworth J, Rogers LA, Moshtael O, Scott K, McManus T, Berrie E, Jeffries DJ, Harris JR, Pinching AJ.

Lancet. 1986 May 24;1(8491):1179-82.

PMID:
2871421
32.

Transmission of a malignant catarrhal fever-like syndrome to sheep: preliminary experiments.

Buxton D, Reid HW, Finlayson J, Pow I, Berrie E.

Res Vet Sci. 1985 Jan;38(1):22-9.

PMID:
4038811
33.

Longitudinal immunological studies on a cohort of initially symptom-free homosexual men in London with respect to HTLV-III serology.

Pinching AJ, Weber JN, Rogers LA, Berrie EL, Jeffries DJ, Harris JR.

Adv Exp Med Biol. 1985;187:67-72. No abstract available.

PMID:
2994421
34.

Malignant catarrhal fever.

Reid HW, Buxton D, Berrie E, Pow I, Finlayson J.

Vet Rec. 1984 Jun 16;114(24):581-3. Review.

PMID:
6431686
35.

A cytotoxic T-lymphocyte line propagated from a rabbit infected with sheep associated malignant catarrhal fever.

Reid HW, Buxton D, Pow I, Finlayson J, Berrie EL.

Res Vet Sci. 1983 Jan;34(1):109-13.

PMID:
6601284
36.

Latency and other consequences of infection of the nervous system with herpes simplex virus.

Hill TJ, Blyth WA, Harbour DA, Berrie EL, Tullo AB.

Prog Brain Res. 1983;59:173-84. No abstract available.

PMID:
6320263

Supplemental Content

Loading ...
Support Center